Literature DB >> 3422052

Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture.

Y Kano1, T Ohnuma, T Okano, J F Holland.   

Abstract

The effects of vincristine (VCR) in combination with methotrexate (MTX) and other antitumor agents were evaluated by cell growth inhibition assay using a human acute lymphoblastic leukemia cell line (MOLT-3). The data were analyzed with the aid of an isobologram using the concept of an envelope of additivity (G. G. Steel and M. J. Peckman, Int. J. Radiat. Oncol., 5:85-91, 1979). Simultaneous exposure of VCR and MTX produced subadditive or mutually protective interactions. Sequential exposure to VCR first followed immediately by MTX produced similar interactions. When the interval of VCR exposure first and then MTX was increased from 0 to 3, 8, and 24 h, the inhibition of cell growth moved from protection and subadditivity to additivity only. The reversed order of exposure to the 2 drugs produced an entirely different picture. Thus, when the interval of MTX exposure first followed by VCR increased from 0 to 3, 8, and 24 h, the inhibitory effects of the combination changed progressively from the area of subadditivity to the area of supraadditivity. When these data were evaluated using median effect plot analyses (T-C. Chou and P. Talalay. In: New Avenues in Developmental Cancer Chemotherapy, pp. 36-64. Orlando, FL: Academic Press, 1987), strongly synergistic interaction of this sequence at space intervals was confirmed. These data show that the synergistic effects were produced only when MTX was followed 8 or 24 h later by VCR. Other schedules were only additive or even antagonistic. Simultaneous exposure of VCR with daunorubicin, 1-beta-D-arabinofuranosylcytosine, or bleomycin also had subadditive and protective effects. VCR, followed by daunorubicin with the interval of 24 h and vice versa, was again subadditive and protective. VCR, followed by 1-beta-D-arabinofuranosylcytosine with the interval of 24 h and vice versa, was again subadditive or additive only. Simultaneous and continuous exposures of VCR with vinblastine or L-asparaginase were only marginally supraadditive.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3422052

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.

Authors:  G Nocentini; A Barzi; P Franchetti
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.

Authors:  Takaaki Oba; Mayu Ono; Hisanori Matoba; Takeshi Uehara; Yoshie Hasegawa; Ken-Ichi Ito
Journal:  Breast Cancer Res Treat       Date:  2021-01-16       Impact factor: 4.872

3.  Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.

Authors:  Fabrice Journé; Nicolas Magné; Carole Chaboteaux; Eric Kinnaert; Frieder Bauss; Jean-Jacques Body
Journal:  Clin Exp Metastasis       Date:  2006-08-16       Impact factor: 5.150

Review 4.  Suppressive drug combinations and their potential to combat antibiotic resistance.

Authors:  Nina Singh; Pamela J Yeh
Journal:  J Antibiot (Tokyo)       Date:  2017-09-06       Impact factor: 2.649

5.  Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines.

Authors:  T Takagi; Y Yazawa; K Suzuki; Y Yamauchi; Y Kano
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

6.  Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

Authors:  Yasuhiko Kano; Miyuki Akutsu; Saburo Tsunoda; Tohru Izumi; Hiroyuki Kobayashi; Hiroyuki Mano; Yusuke Furukawa
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

7.  Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.

Authors:  Michael Fiegl; Lars H Lindner; Matthias Juergens; Hansjoerg Eibl; Wolfgang Hiddemann; Jan Braess
Journal:  Cancer Chemother Pharmacol       Date:  2007-10-06       Impact factor: 3.333

8.  The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.

Authors:  Shoko Goto; Hiroaki Goto; Tomoko Yokosuka
Journal:  Int J Hematol       Date:  2016-02-17       Impact factor: 2.490

9.  The effects of ICRF-154 in combination with other anticancer agents in vitro.

Authors:  Y Kano; T Narita; K Suzuki; M Akutsu; K Suda; S Sakamoto; Y Miura
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

10.  Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells.

Authors:  Bui Thi Kim Ly; Hoang Thanh Chi; Makoto Yamagishi; Yasuhiko Kano; Yukihiko Hara; Kazumi Nakano; Yuko Sato; Toshiki Watanabe
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.